Smith & Nephew SNATS, Inc. (NYSE:SNN) to Issue Dividend of $0.48

Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report) declared a dividend on Thursday, March 5th. Shareholders of record on Friday, March 27th will be paid a dividend of 0.482 per share by the medical equipment provider on Wednesday, May 27th. This represents a dividend yield of 281.0%. The ex-dividend date is Friday, March 27th.Get Smith & Nephew SNATS alerts:Santa Rally comes early for these stocksSmith & Nephew SNATS has raised its dividend payment by an average of 0.0%annually over the last three years. Smith & Nephew SNATS has a payout ratio of 26.0% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Smith & Nephew SNATS to earn $2.00 per share next year, which means the company should continue to be able to cover its $0.57 annual dividend with an expected future payout ratio of 28.5%. Smith & Nephew SNATS Price PerformanceNYSE SNN traded down $0.60 during mid-day trading on Friday, hitting $34.25. The company's stock had a trading volume of 414,074 shares, compared to its average volume of 955,770. The company has a current ratio of 2.57, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS has a 52-week low of $23.91 and a 52-week high of $38.79. The stock's fifty day simple moving average is $34.40 and its two-hundred day simple moving average is $34.95. Institutional Trading of Smith & Nephew SNATSSurgical Centers, Med-Tech Stocks Up On Pent-Up Surgical DemandA number of hedge funds have recently modified their holdings of SNN. Garner Asset Management Corp purchased a new stake in shares of Smith & Nephew SNATS during the 4th quarter worth about $27,000. Arax Advisory Partners boosted its stake in shares of Smith & Nephew SNATS by 142.6% during the 4th quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider's stock worth $32,000 after acquiring an additional 569 shares in the last quarter. Advisors Asset Management Inc. bought a new position in shares of Smith & Nephew SNATS in the fourth quarter worth about $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in Smith & Nephew SNATS in the 3rd quarter valued at approximately $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Smith & Nephew SNATS during the fourth quarter worth approximately $43,000. Hedge funds and other institutional investors own 25.64% of the company's stock. About Smith & Nephew SNATS (Get Free Report)Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing. 3 Healthcare Dividend Payers With Big Price GrowthIn its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.Further ReadingFive stocks we like better than Smith & Nephew SNATSBNZI stands out as a Zacks Buy. Earnings momentum and analyst upgrades align“Fed Proof” Your Bank Account with THESE 4 Simple StepsWhat a Former CIA Agent Knows About the Coming CollapseYour name isn't on our protected list yetWhat Expenses Can Be Deducted From Capital Gains Tax This Year?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Smith & Nephew SNATS Right Now?Before you consider Smith & Nephew SNATS, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew SNATS wasn't on the list.While Smith & Nephew SNATS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here